Hikma Pharmaceuticals (GB:HIK) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Hikma Pharmaceuticals PLC has successfully acquired Xellia Pharmaceuticals’ US finished dosage form business, which includes a commercial portfolio, a manufacturing facility, and an R&D center, for $135 million with up to $50 million in additional payments based on milestones. The acquisition aims to bolster Hikma’s US injectables business, enhance its portfolio with advanced manufacturing technologies, and is expected to contribute positively to earnings after the first year. This strategic move is projected to support the company’s growth and long-term benefits in the pharmaceutical industry.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
